Kura Oncology, Inc. (NASDAQ:KURA) on Wednesday announced $50 million financing tied to advancing its menin-inhibition strategy.
Launches Caspian Therapeutics With $50 Million Financing
Kura said it is launching Caspian Therapeutics alongside a $50 million financing led by BVF Partners, with participation from the T1D Fund, Invus, Montanova, Eli Lilly and Co. (NYSE:LLY), Kura Oncology, members of Kura’s leadership team, and other investors.
The stated goal is to advance the company’s work in menin inhibition and expand development capacity around that approach.
Development Of Lead Asset KO-7246
Caspian was established around KO-7246, a next-generation, highly selective menin inhibitor purpose-designed for chronic metabolic diseases, together with related intellectual property and know-how contributed by Kura.
The financing is expected to fund advancement of KO-7246 through IND-enabling development and initial clinical proof-of-concept in diabetes, as well as support the advancement of a second menin inhibitor development candidate for diabetes and cardiometabolic diseases.
Operational Structure And Ownership Terms
Caspian will operate with dedicated leadership and external capital with access to Kura’s research, development, and corporate capabilities under an intercompany services arrangement. Kura will retain approximately half ownership of Caspian and board representation.
Analyst Consensus & Recent Actions: The stock carries a Buy rating with an average price forecast of $25.00. Recent analyst moves include:
- Citizens: Market Outperform (Maintains Price Forecast at $24.00) (August 24).
- Wedbush: Outperform (Raises Price Forecast to $38.00) (August 13).
How Kura Oncology Ranks On Momentum Versus The Market
Below is the Benzinga Edge scorecard for Kura Oncology, highlighting its strengths and weaknesses compared to the broader market:
- Momentum: Bullish (Score: 92.68) — The stock is showing strong relative strength versus the broader market.
The Verdict: Kura Oncology’s Benzinga Edge signal reveals a momentum-driven story, with price action doing most of the heavy lifting right now.
With other factor scores not available here, the clean takeaway is that trend-followers may stay interested as long as the stock holds its key moving averages and doesn’t lose momentum.
KURA Price Action: Kura Oncology shares were down 1.04% at $12.39 at the time of publication on Wednesday, according to Benzinga Pro data.
Photo: Shutterstock
